Skip to main content

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non-surgical birth control continues --

ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2024 and provides a corporate update.

Corporate Highlights from 1Q 2024 to date

  • Company announced positive topline data from pivotal trial for FDA-cleared FemaSeed® for the treatment of infertility.
  • Company announced the first in-office commercial procedure with FDA-cleared FemaSeed infertility solution at a former investigative site.
  • Appointed Richard Spector as Chief Commercial Officer.
  • Initiated enrollment in pivotal trial (NCT05977751) of our permanent birth control candidate FemBloc at two academic sites, for a total of six active sites, the maximum permitted in the first stage.

“Femasys is well positioned to commercialize our infertility portfolio, led by FemaSeed in 2024 with promising top line data from the FemaSeed pivotal trial that was more than double the historic intrauterine insemination (IUI) pregnancy rates for male factor infertility (i.e., low sperm count). We are focused on completing recruitment of the commercial team and ramping up commercial operations, while continuing to support enrollment in our pivotal trial for FemBloc, our proprietary solution for permanent non-surgical birth control,” said Femasys’ CEO Kathy Lee-Sepsick. “We believe we have sufficient cash to fund operations into the second half of 2025, allowing us to continue our track record of achieving our stated milestones and moving our mission forward to deliver innovative purposely engineered solutions for women’s health that are safe, effective, accessible, and affordable.”

Financial Results for Quarter Ended March 31, 2024

  • Research and development expenses increased by $233,292 to $1,770,731 in Q1 of 2024 from $1,537,439 in Q1 of 2023
  • Sales decreased by $22,844 to $271,140 in Q1 of 2024 from $293,984 in Q1 of 2023
  • Net loss was $3,599,510 or $0.17 per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2024, compared to net loss of $2,946,257, or $0.25 per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2023
  • Cash and cash equivalents as of March 31, 2024 was $17,835,968 and the Company had an accumulated deficit of $111,981,139. The Company expects, based on its current operating plan, that its existing cash and cash equivalents will be sufficient to fund its ongoing operations into the second half of 2025

For more information, please refer to the Company’s Form 10-Q filed May 9, 2024, which can be accessed on the SEC website.

Condensed Balance Sheets
Assets March 31,
 December 31,
Current assets:    
 Cash and cash equivalents$17,835,968  21,716,077 
 Accounts receivable, net 120,529  98,906 
 Inventory, net 971,297  667,118 
 Prepaid and other current assets 955,539  695,879 
     Total current assets 19,883,333  23,177,980 
Property and equipment, at cost:    
 Leasehold improvements 1,212,417  1,212,417 
 Office equipment 47,308  47,308 
 Furniture and fixtures 417,654  414,303 
 Machinery and equipment 2,582,220  2,559,356 
 Construction in progress 569,723  423,077 
       4,829,322  4,656,461 
Less accumulated depreciation (3,615,405) (3,545,422)
     Net property and equipment 1,213,917  1,111,039 
Long-term assets:    
 Lease right-of-use assets, net 2,227,561  2,380,225 
 Intangible assets, net of accumulated amortization 33,115   
 Other long-term assets 1,013,034  1,086,581 
     Total long-term assets 3,273,710  3,466,806 
     Total assets$24,370,960  27,755,825 

Condensed Balance Sheets
Liabilities and Stockholders’ Equity  March 31,
 December 31,
Current liabilities:    
 Accounts payable$1,095,730  1,137,823 
 Accrued expenses 673,457  1,444,296 
 Clinical holdback – current portion 93,376  65,300 
 Lease liabilities – current portion 494,967  406,636 
     Total current liabilities 2,357,530  3,054,055 
Long-term liabilities:    
 Clinical holdback – long-term portion 30,389  54,935 
 Convertible notes payable, net (including related parties) 4,472,456  4,258,179 
 Lease liabilities – long-term portion 1,902,991  2,036,067 
     Total long-term liabilities 6,405,836  6,349,181 
     Total liabilities 8,763,366  9,403,236 
Commitments and contingencies    
Stockholders’ equity:    
 Common stock, $.001 par, 200,000,000 authorized,    
  22,216,570 shares issued and 22,099,347 outstanding as of   
  March 31, 2024; and 21,774,604 shares issued    
  and 21,657,381 outstanding as of December 31, 2023 22,217  21,775 
 Treasury stock, 117,223 common shares (60,000) (60,000)
 Warrants   2,631,838  2,787,137 
 Additional paid-in-capital 124,994,678  123,985,306 
 Accumulated deficit (111,981,139) (108,381,629)
     Total stockholders’ equity 15,607,594  18,352,589 
     Total liabilities and stockholders' equity$24,370,960  27,755,825 

Condensed Statements of Comprehensive Loss
       Three Months Ended March 31,
       2024  2023 
Sales   $271,140  293,984 
Cost of sales (excluding depreciation expense) 88,532  105,120 
Operating expenses:    
 Research and development 1,770,731  1,537,439 
 Sales and marketing 300,487  244,896 
 General and administrative 1,502,804  1,315,137 
 Depreciation and amortization 71,228  133,066 
     Total operating expenses 3,645,250  3,230,538 
     Loss from operations (3,462,642) (3,041,674)
Other income (expense):    
 Interest income 224,684  97,089 
 Interest expense (361,552) (1,672)
     Total other income (expense) (136,868) 95,417 
     Net loss$(3,599,510) (2,946,257)
Net loss attributable to common stockholders, basic and diluted$(3,599,510) (2,946,257)
Net loss per share attributable to common stockholders, basic and diluted$(0.17) (0.25)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 21,775,357  11,872,255 

About Femasys

Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at, or follow us on XFacebook and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.


Gene Mannheimer

Media Contact:
Kati Waldenburg 

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.